ExpressPoints:
Combination Therapy in Renal Cell Carcinoma: Expert Guidance to Individualize Treatment and Improve Outcomes

Gain key clinical insights fast, with this short slideset from CCO on individualizing and optimizing treatment for patients with advanced RCC.
Neeraj Agarwal, MD
Eric Jonasch, MD
Elizabeth R. Plimack, MD, MS
Format: Microsoft PowerPoint (.ppt)
File Size: 1.84 MB
Released: June 16, 2021

Acknowledgements

Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC
NCCN Logo

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Eisai
Exelixis, Inc.
Merck Sharp & Dohme Corp.

Related Content

Use this web-based tool to see recommendations from 5 experts on treating patients with bladder cancer.

Matthew Galsky, MD person default Shilpa Gupta, MD Matthew I. Milowsky, MD Elizabeth R. Plimack, MD, MS person default Arlene O. Siefker-Radtke, MD Released: July 19, 2021

On-demand webcast on PARP inhibitor combination therapies in prostate cancer featuring 3 faculty experts presented by Clinical Care Options (CCO)

Charles J. Ryan, MD
Program Director
person default Wassim Abida, MD, PhD Joaquin Mateo, MD, PhD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: July 7, 2021 Expired: July 6, 2022

Dr. Charles J. Ryan discusses the rationale and evidence for PARP inhibitor combinations in prostate cancer, from Clinical Care Options (CCO)

Charles J. Ryan, MD Released: July 2, 2021

Downloadable PDF with highlights from a CCO podcast on PARP inhibitors and emerging combination strategies in prostate cancer.

Charles J. Ryan, MD
Program Director
person default Wassim Abida, MD, PhD Joaquin Mateo, MD, PhD
Released: June 30, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue